THAC primarily focuses on age-related diseases,
such as:
Type 2 Diabetes Mellitus,
Neuropathy, and
Alzheimer’s diseases
The Problem
Age related diseases are a global epidemic as the society grows older
Metabolic dysfunction is a key factor in most aged-related diseases
90%
of older adults have at least one chronic condition, nearly 80% have at least 2
Global epidemic
Cardiovascular, obesity, diabetes and Alzheimer’s are global epidemic diseases
80%
Age related diseases represent 80% of the US Medicare budget
$30 trillion
Over $30 trillion over the next 20 years
THAC envisions that drug candidates will lead to a major breakthrough in the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g., diabetic foot wounds, amputations) by fighting insulin resistance, the root cause of T2DM, through a unique and innovative mechanism of action targeting oxidation and inflammation and directly acting on the microbiota.
THAC drug candidates are intended to delay disease progression, delay premature death, prevent T2DM complications (i.e., peripheral neuropathy, e.g., diabetic foot wounds and amputations), and improve patient quality of life.
THAC develops GMP approved, first-in-class,
first-in-man molecules
THAC develops biological and recombinant drug candidates with the active ingredient ALF-5755 (recombinant human protein derived from C-type lectin Reg3α), a GMP approved, first-in-class, first-in-man molecule.
THAC innovative drug candidates have unique biological properties, a combination of anti-oxidative ROS-scavenger and anti-inflammatory activity to tackle insulin resistance, the root cause of Type 2 diabetes mellitus, and muscle glucose uptake, decrease fat lean without overall weight loss and restore gut microbiota composition.
THAC is a resident at The Institute of Diabetes,
Paris (France)
and at the University of South Florida (US)
The Founders
THAC is a mature biopharmaceutical company. THAC was created by Prof. Christian Bréchot MD & PhD, Dr Gilles Amouyal MD & PhD, Dr Paul Amouyal MD, Prof. Christophe Magnan PhD,
Christian Bréchot
MD & PhD
CEO/ Co-Founder
Gilles Amouyal
MD & PhD
Co-Founder
Paul Amouyal
MD
Co-Founder
Christophe Magnan
PhD
Head of Research/ Co-Founder
Scientific Consultants
Dr. Aurélie Joly-Amado, PHD
Research Scientist University of South Florida USA
Consultant on neurodegenerative diseases
Dr. Céline Cruciani-Guglielmacci, PhD
Professor University Paris Cité – Paris France
Consultant on Metabolic syndrome and diabetes
Explore Our Blog
[PRESS RELEASE] Lancement du CSIS : Lyse Santoro, Personnalité Qualifiée du Conseil Stratégique des Industries de Santé (CSIS) 2021, THAC participe aux travaux du CSIS
[PRESS RELEASE] Lancement du Conseil stratégique des industries de[…]
Contact us
♦ Our location in France
Cochin Hospital – APHP
Incubateur Paris Biotech Santé
24 Boulevard du Faubourg Saint Jacques
75014 Paris, France
♦ Our location in the United States
University of South Florida
USF Connect Incubator
3702 Spectrum Blvd.
Tampa, FL 33612, USA